SCHEMBL29246322

SCHEMBL29246322

COC(=O)c1ccc(F)cc1Oc1cc2c(F)cn(COCC[Si](C)(C)C)c2nc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 4/20 0.36
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35
▸ PLA2G2A P14555 3/20 0.34
▸ FFAR4 Q5NUL3 1/20 0.34
▸ MAPT P10636 2/20 0.33
▸ LMNA P02545 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ THRB P10828 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ HPGD P15428 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ CASP3 P42574 1/20 0.32
▸ SENP8 Q96LD8 1/20 0.32
▸ SENP7 Q9BQF6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31019222 1.00 DGAT1 (0.36) DGAT1NPC1RAB9AKMT2ARXFP1
SCHEMBL29246501 0.91 DGAT1 (0.34) DGAT1NPC1KMT2AMAPT
SCHEMBL30421232 0.75 DGAT1 (0.34) DGAT1NPC1
SCHEMBL1958044 0.74 DGAT1 (0.37) DGAT1NPC1RAB9AKMT2ARXFP1
SCHEMBL1957574 0.73 DGAT1 (0.36) DGAT1NPC1RAB9AKMT2ARXFP1
SCHEMBL30421153 0.73 DGAT1 (0.39) DGAT1
SCHEMBL1958266 0.71 FGFR1 (0.39) DGAT1NPC1RAB9APLA2G2AFFAR4
SCHEMBL31497518 0.70 DGAT1 (0.39) DGAT1NPC1RAB9ARXFP1MAPT
SCHEMBL31748662 0.70 DGAT1 (0.38) DGAT1NPC1KMT2AMAPTLMNA
SCHEMBL30612031 0.70 KDM4E (0.44) DGAT1NPC1PLA2G2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122191-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2025-04-17 — — US disclosed
CN-118284608-A Compounds as BCL-2 inhibitors 重庆复创医药研究有限公司 2024-07-02 — — CN disclosed
CN-118215661-A Compounds as BCL-2 inhibitors 重庆复创医药研究有限公司 2024-06-18 — — CN disclosed
WO-2024032776-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2024-02-15 — — WO disclosed
WO-2023088167-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON PHARMACEUTICALS, LTD. (CN) 2023-05-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122191-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 DGAT1 1390/4885NPC1 1649/4885RAB9A 3044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback